Publications by authors named "Komal Nadeem"
Background: Tocilizumab is an interleukin-6 receptor antagonist hypothesized to blunt the uncontrolled immune response, cytokine release syndrome, in severe COVID-19 and prevent attributable morbidity and mortality. Objective: The objective of this study was to assess the impact of tocilizumab on clinical outcomes in COVID-19-associated cytokine release syndrome.
Methods: Single-center, retrospective cohort study assessing sixty-nine adult patients receiving tocilizumab for suspected COVID-19 cytokine release syndrome.
Article Synopsis
- Systemic colistin is used for drug-resistant lower respiratory tract infections, and nebulized colistin enables direct delivery to minimize side effects.
- A study analyzed data from patients treated with nebulized colistin from 2016 to 2018, focusing on adverse reactions and safety compared to systemic administration.
- The study found that nebulized colistin resulted in very few adverse events, supporting its use as a safe treatment option for lower respiratory tract infections.